Charting view, page-5

Have a read of these 3 notes from FiftyOne Capital

(They're free - you just need to input your email address to access)

http://www.fiftyonecapital.com/paradigm-201903/2019/3/8/paradigm-biopharmaceuticals-ltd

Quote:

Given the unmet need for OA and the growing number of people who have already had a positive experience with the drug on the SAS program, it's likely sales will ramp up very quickly. This could mean first revenues as early as 2020. Treating only 10,000 people at a price of $2,500 per patient, would generate revenue of $25m for Paradigm. Given there is over 2 million people suffering from OA in Australia this number could be far higher.